Glucosylceramide Synthase Inhibitors Pipeline Insight Report 2021 Featuring Idorsia Pharmaceuticals & Sanofi and Lucerastat, Venglustat & Sinbaglustat – ResearchAndMarkets.com

Glucosylceramide Synthase Inhibitors Pipeline Insight Report 2021 Featuring Idorsia Pharmaceuticals & Sanofi and Lucerastat, Venglustat & Sinbaglustat – ResearchAndMarkets.com




Glucosylceramide Synthase Inhibitors Pipeline Insight Report 2021 Featuring Idorsia Pharmaceuticals & Sanofi and Lucerastat, Venglustat & Sinbaglustat – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Glucosylceramide Synthase Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Glucosylceramide synthase inhibitors – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Glucosylceramide synthase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Glucosylceramide synthase inhibitors R&D. The therapies under development are focused on novel approaches for Glucosylceramide synthase inhibitors.

Glucosylceramide synthase inhibitors Emerging Drugs Chapters

This segment of the Glucosylceramide synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glucosylceramide synthase inhibitors Emerging Drugs

Lucerastat: Idorsia Pharmaceuticals

Lucerastat inhibits glycolipid biosynthesis. Lucerastat is an orally bioavailable inhibitor of glucosylceramide synthase. Lucerastat is being developed by the biopharmaceutical company Idorsia for the treatment of Fabry disease. It is currently in Phase III stage of development. It acts as Glucosylceramide synthase inhibitor. In 2018, Lucerastat has received Orphan Drug designation in the US and in the EU for Fabry disease.

Venglustat: Sanofi

Venglustat is an investigational oral glucosylceramide synthase inhibitor in development for multiple diseases with disruptions in the GSL metabolic pathway. These diseases include three lysosomal storage disorders: Gaucher disease type 3, Fabry disease and GM2 gangliosidosis as well as autosomal dominant polycystic kidney (ADPKD) disease and GBA-associated Parkinson’s disease.

The FDA has granted Fast Track designation for the development of venglustat as an investigational therapy for the treatment of Gaucher disease type 3, Fabry disease and GM2 gangliosidosis. Sanofi has been granted Orphan Drug Designation for venglustat in Europe and the U.S. for treatment of patients with Fabry disease, ADPKD, Gaucher disease and GM2 gangliosidosis.

Glucosylceramide synthase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Glucosylceramide synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Glucosylceramide synthase inhibitors

There are approx. 5+ key companies which are developing the Glucosylceramide synthase inhibitors. The companies which have their Glucosylceramide synthase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Idorsia Pharmaceuticals.

Key Players

  • Idorsia Pharmaceuticals
  • Sanofi

Key Products

  • Lucerastat
  • Venglustat
  • Sinbaglustat

Key Topics Covered:

Introduction

Executive Summary

Glucosylceramide synthase inhibitors: Overview

  • Structure
  • Mechanism of Action

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Glucosylceramide synthase inhibitors- Analytical Perspective

In-depth Commercial Assessment

  • Glucosylceramide synthase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Glucosylceramide synthase inhibitors Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Lucerastat: Idorsia Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)

  • Comparative Analysis

Sinbaglustat: Idorsia Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products

  • Comparative Analysis

Glucosylceramide synthase inhibitors Key Companies

Glucosylceramide synthase inhibitors Key Products

Glucosylceramide synthase inhibitors- Unmet Needs

Glucosylceramide synthase inhibitors- Market Drivers and Barriers

Glucosylceramide synthase inhibitors- Future Perspectives and Conclusion

Glucosylceramide synthase inhibitors Analyst Views

Glucosylceramide synthase inhibitors Key Companies

Appendix

Companies Mentioned

  • Idorsia Pharmaceuticals
  • Sanofi

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/s23qd2

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900